GYNECOLOGICAL CANCERS

REFERENCES

• Bast R. C., Jr., Brewer M., Zou C., Hernandez M., Daley M., Ozols R., Lu K., Lu Z., Badgwell D., Mills G. B., Skates S., Zhang Z., Chan D., Lokshin A., Yu Y. Prevention and early detection of ovarian cancer: Mission impossible?. Recent Results in Cancer Research 2007; 174: 91–100
   PubMedGoogle Scholar
• Alberts D. S., Liu P. Y., Hannigan E. V., O'Toole R., Williams S. D., Young J. A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 1996; 335: 1950–1955
   PubMed Web of Science ®Google Scholar
• Markman M., Bundy B. N., Alberts D. S., Fowler J. M., Clark-Pearson D. L., Carson L. F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 2001; 19: 1001–1007
   PubMed Web of Science ®Google Scholar
• Armstrong D., Bundy B., Wenzel L., Huang H. Q., Baergen R., et al. Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin, and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group study. N. Engl. J. Med. 2006; 354: 34–43
   PubMed Web of Science ®Google Scholar
• Miyagi Y., Fujiwara K., Kigawa J., et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin-A Sankai Gynecology Study Group (SGSG) study. Gynecol. Oncol. 2005; 99: 591–596
   PubMed Web of Science ®Google Scholar
• Fujiwara K., Suzuki S., Ishikawa H., Oda T., Aotani E., Kohno I. Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube. Int. J. Gynecol. Cancer. 2005; 15: 426–431
   PubMed Web of Science ®Google Scholar
• Fujiwara K., Sakuragi N., Suzuki S., Yoshida N., Maehata K., Nishiya M., Koshida T., Sawai H., Aotani E., Kohno I. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol. Oncol. 2003; 90: 637–643
   PubMed Web of Science ®Google Scholar
• Fujiwara K., Nagao S., Kigawa J., Noma J., Akamatsu N., Miyagi Y., Numa F., Okada M., Aotani E., Terakawa N. Comparative phase II study of intraperitoneal (IP) versus intravenous (IV) carboplatin administration with IV paclitaxel in patients with bulky residual disease after primary debulking surgery for epithelial ovarian or primary peritoneal cancer: A Sankai Gynecology Study Group (SGSG) study. Proc. ASCO 2007, Abstract #5584
   Google Scholar
• Krasner C. N., Seiden M. V., Fuller A. F., Supko J. G., Roche M., Kendall D. L., Lee J., Berkowitz R., Berlin S., Matulonis U. A. Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer. Proc. ASCO 2007, Abstract #5521
   Google Scholar
• Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J. Clin. 2007; 57: 43–66
   PubMed Web of Science ®Google Scholar
• Bristow R. E., et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 2002; 20(5)1248–1259
   PubMed Web of Science ®Google Scholar
• McGuire W. P., Hoskins W. J., Brady M. F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996; 334: 1–6
   PubMed Web of Science ®Google Scholar
• Ozols R., Bundy B., Greer B. E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 2003; 21(17)3194–3200
   PubMed Web of Science ®Google Scholar
• Vasey P. A., Jayson G. C., Gordon A., Gabra H., Coleman R., Atkinson R., Parkin D., Paul J., Hay A., Kaye S. B. Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. Nov 17, 2004; 96(22)1682–1691
   PubMed Web of Science ®Google Scholar
• Alberts D. S., Liu P. Y., Hannigan E. V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 1996; 335: 1950–1955
   PubMed Web of Science ®Google Scholar
• Markman M., Bundy B. N., Alberts D. S., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 2001; 19: 1001–1007
   PubMed Web of Science ®Google Scholar
• Armstrong D., et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. New Engl. J. Med., 2006; 354: 34–43
   PubMed Web of Science ®Google Scholar
• Markman M., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 2003; 21(13)2460–2465
   PubMed Web of Science ®Google Scholar
• Herzog T. J. Recurrent ovarian cancer: how important is it to treat to disease progression?. Clin. Cancer Res. 2004; 10: 7439–7449
   PubMed Web of Science ®Google Scholar
• Suhrland L. G., Weisberger A. S. Intracavitary 5-fluorouracil in malignant effusions. Arch. Intern. Med. 1965; 116: 431–433
   PubMed Web of Science ®Google Scholar
• Dedrick R. L., Myers C. E., Bungay P. M., DeVita V. T., Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 1978; 62: 1–9
   PubMedGoogle Scholar
• Kraft A. R., Tompkins R. K., Kaplan R. A. Peritoneal electrolyte absorption: Analysis of portal, systemic venous and lymphatic transport. Surgery 1968; 64: 148–153
   PubMed Web of Science ®Google Scholar
• Bergman F. Carcinoma of the ovary: A clinicopathological study of 86 autopsied cases with special reference to mode of spread. Acta. Obstet. Gynecol. Scand. 1966; 45: 211–231
   PubMed Web of Science ®Google Scholar
• Markman M. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Crit. Rev. Oncol./Hematol. 1993; 14: 15–28
   PubMed Web of Science ®Google Scholar
• Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs 2001; 61(8)1057–1065
   PubMed Web of Science ®Google Scholar
• Howell S. B., Pfeifle C. L., Wung W. E., et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 1982; 97(6)845–851
   PubMed Web of Science ®Google Scholar
• Casper E. S., Kelsen D. P., Alcock N. W., Lewis J. L. Jr. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the IV route. Cancer Treat. Rep. 1983; 67(3)235–238
   Google Scholar
• Fujiwara K., Markman M., Morgan M., Coleman R. L. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol. Oncol. 2005; 97(1)10–15
   PubMed Web of Science ®Google Scholar
• Markman M., Rowinsky E., Hakes T., et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J. Clin. Oncol. 1992; 10(9)1485–1491
   PubMed Web of Science ®Google Scholar
• Francis P., Rowinsky E., Schneider J., Hakes T., Hoskins W., Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group Pilot Study. J. Clin. Oncol. 1995; 13(12)2961–2967
   PubMed Web of Science ®Google Scholar
• Markman M., Reichman B., Hakes T., et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J. Clin. Oncol. 1991; 9(10)1801–1805
   PubMed Web of Science ®Google Scholar
• Howell S. B., Zimm S., Markman M., et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J. Clin. Oncol. 1987; 5(10)1607–1612
   PubMed Web of Science ®Google Scholar
• Markman M., Reichman B., Hakes T., et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J. Clin. Oncol. 1992; 10(9)1479–1484
   PubMed Web of Science ®Google Scholar
• Barakat R. R., Sabbatini P., Bhaskaran D., et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J. Clin. Oncol. 2002; 20(3)694–698
   PubMed Web of Science ®Google Scholar
• Alberts D. S., Liu P. Y., Hannigan E. V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 1996; 335(26)1950–1955
   PubMed Web of Science ®Google Scholar
• Markman M., Bundy B. N., Alberts D. S., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 2001; 19(4)1001–1007
   PubMed Web of Science ®Google Scholar
• Armstrong D. K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006; 354(1)34–43
   PubMed Web of Science ®Google Scholar
• Elit L., Oliver T. K., Covens A., et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 2007; 109(4)692–702
   PubMed Web of Science ®Google Scholar
• Marth C., Walker J. L., Barakat R. R., et al. Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. Cancer 2007; 109(4)645–649
   PubMed Web of Science ®Google Scholar
• Trimble E. L., Alvarez R. D. Intraperitoneal chemotherapy and the NCI clinical announcement. Gynecol Oncol. 2006; 103: S18–S19, (2 Suppl 1)
   PubMed Web of Science ®Google Scholar
• Markman M., Walker J. L. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J. Clin. Oncol. 2006; 24(6)988–994
   PubMed Web of Science ®Google Scholar
• Walker J. L., Armstrong D., Huang H. Q., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecol. Oncol. 2006; 100: 27–32
   PubMed Web of Science ®Google Scholar
• Markman M., Belinson J. A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers. J. Cancer Res. Clin. Oncol. 2005; 131(1)26–30
   PubMed Web of Science ®Google Scholar
• Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F. M., Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995; 13: 1777–1785
   PubMed Web of Science ®Google Scholar
• Muggia F. M., Hainsworth J. D., Jeffers S., et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 1997; 15: 987–993
   PubMed Web of Science ®Google Scholar
• Gordon A. N., Granai C. O., Rose P. G., et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol. 2000; 18: 3093–3010
   PubMed Web of Science ®Google Scholar
• Gordon A. N., Tonda M., Sun S., Rackoff W. Doxil Study 30-49 investigators. Long-term survival for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynec. Oncol. 2004; 95: 1–8
   PubMed Web of Science ®Google Scholar
• Muggia F. M., Blessing J. A., Sorosky J., Reid G. C. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 2002; 20: 2360–2364
   PubMed Web of Science ®Google Scholar
• Vergote I., Finkler N., del Campo J., et al. Single agent, canfosfamide (C, TLK286) vs pegylated liosomal doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results. Proc ASCO 2007, (abstract LBA5528)
   Google Scholar
• O'Byrne K. J., Bliss P., Graham J. D., et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane-naïve relapsed ovarian cancer. Proc ASCO 2002; 21: 203a, (abstract 808)
   Google Scholar
• Andreopoulou E., Gaiotti D., Kim E., et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann. Oncol. 2007; 18(4)716–21
   PubMed Web of Science ®Google Scholar
• Gabizon A., Isaacson R., Rosengarten O., et al. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol Jun 5, 2007, [Epub ahead of print]; also Proc. ASCO 2206
   PubMed Web of Science ®Google Scholar
• Lademan J., Martschick A., Jacobi U., et al. Investigation of doxorubicin on the skin: a spectroscopic study to understand the pathogenesis of PPE. Proc. ASCO. 2005; 24: 477s, (abstract 5093)
   Google Scholar
• Tedjarati S., Sayer R., Boulware D., Apte S. Regional cooling protocol significantly reduces the incidence of pegylated liposomal doxorubicin induced palmar-plantar erythrodysesthesias (PPE) in patients with recurrent epithelial ovarian cancer. Int. J. Gynecol. Cancer. 2006; 16: 686, (suppl 3) (abstract 312)
   PubMedGoogle Scholar
• Mangili C., Gentile C., Rabaiotti E., et al. The role of regional cooling on prevention of palmar-plantar erythrodysesthesia in patients treated with pegylated liposomal doxorubicin. Int. J. Gynecol. Cancer. 2006; 16: 790, (suppl 3) (abstract 677)
   Google Scholar
• Klein P., Wasserheit C., Hochster H., et al. Apparent protection of doxil skin and oral toxicities when combined with cisplatin (CDDP): Results of a Phase I study. Proc. ASCO. 1999, (abstract 835)
   Google Scholar
• Klein P., Hamilton A., Lyass O., et al. Phase I stdies of doxil combined with cisplation: Efficacy in epithelial ovarian (Eoc) and Fallopian tube (Ftc) cancers. Proc. ASCO 2000, (abstract 1623C)
   Google Scholar
• Lyass O., Hubert A., Gabizon A. A. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin. Cancer Res. 2001; 7(10)3040–3046
   PubMed Web of Science ®Google Scholar
• Hamilton A. L., Pavlick A., Volm M., et al. Pegylated liposomal doxorubicin (PLD) and carboplatin: a phase I study of combination therapy with maintenance PLD. Proc. ASCO. 2003; 22: 494, (abstract 1986)
   Google Scholar
• Ferrero J. M., Weber B., Geay J. F., Lepille D., Orfeuvre H., Combe M., Mayer F., Leduc B., Bourgeois H., Paraiso D., Pujade-Lauraine E. Second-linechemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol. 2007; 18(2)263–268
   PubMed Web of Science ®Google Scholar
• Du Bois A., Burges A., Meier W., Pfisterer J., Schmalfeldt B., Richter B., Jackisch C., Staehle A., Kimmig R., Elser G. Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom. Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR). Ann. Oncol. 2006; 17(1)93–96
   Google Scholar
• Mirchandani D., Hochster H., Hamilton A., et al. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin. Cancer Res. 2005; 11(16)5912–5919
   PubMed Web of Science ®Google Scholar
• Safra T., Muggia F., Jeffers S., et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. 2000; 11(8)1029–33
   PubMed Web of Science ®Google Scholar
• Pearcey R., Brundage M., Drouin P., et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J. Clin. Oncol. 2002; 20: 966–972
   PubMed Web of Science ®Google Scholar
• Eifel P. J., Winter K., Morris M., et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01. J. Clin. Oncol. 2004; 22: 872–88
   PubMed Web of Science ®Google Scholar
• Long H. J., 3rd, Bundy B. N., Grendys E. C., Jr., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 2005; 23: 4626–4633
   PubMed Web of Science ®Google Scholar
• Monk B. J., Huang H. Q., Cella D., et al. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 2005; 23: 4617–4625
   PubMed Web of Science ®Google Scholar
• Oxaliplatin plus paclitaxel for recurrent and metastatic cervical cancer (CC). New York Cancer Consortium Trial P5840. Journal of Clinical Oncology 2007; 25: 18S, 2007 ASCO Annual Meeting Proceedings Part I(June 20 Supplement), 5549
   Google Scholar
• Kaufman B., Segal A., Levi-Lahad, et al. Different biological effect of BRCA1 and BRCA2 mutations in Ashkenazi breast and ovarian cancer patients. Ann. Oncol. 2000; 11, (Suppl 4), Abstract 360
   Web of Science ®Google Scholar
• Ford D., Easton D. F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families, The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 1998; 62: 676–689
   PubMed Web of Science ®Google Scholar
• The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst 1999; 91: 1310–1316
   PubMed Web of Science ®Google Scholar
• Risch H. A., McLaughlin J. R., Cole D. E., et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 2001; 68: 700–710
   PubMed Web of Science ®Google Scholar
• Moslehi R., Chu W., Karlan B., et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am. J. Hum. Genet. 2000; 66: 1259–1272
   PubMed Web of Science ®Google Scholar
• Boyd J., Sonoda Y., Federici M. G., et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000; 283: 2260–2265
   PubMed Web of Science ®Google Scholar
• Leong C. O., Vidnovic N., DeYoung M. P., Sgroi D., Ellisen L. W. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J. Clin. Invest. May, 2007; 117(5)1370–80, Epub 2007 Apr 19
   PubMed Web of Science ®Google Scholar